| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Ubiquitin-conjugating enzyme Ubch5 (UBE2D); NF-κB and MAPK signaling pathways. 1beta-Hydroxyalantolactone is a potent, covalent inhibitor of ubiquitin-conjugating enzyme Ubch5, with Kd values of 5.189 μM (Ubch5a), 3.578 μM (Ubch5b), and 2.577 μM (Ubch5c). The compound inhibits NF-κB and MAPK signaling pathways, leading to reduced expression of pro-inflammatory cytokines (TNF-α, IL-17, IFN-γ) and induction of apoptosis in cancer cells. Its anti-inflammatory effects are mediated through these pathways.
|
|---|---|
| ln Vitro |
In mice exposed to 2,4-dinitrochlorobenzene, 1beta-hydroxyalantolactone reduces skin lesions resembling atopic dermatitis[1].
1beta-Hydroxyalantolactone inhibits NF-κB and MAPK signaling pathways, reducing expression of pro-inflammatory cytokines including TNF-α, IL-17, and IFN-γ. It is a potent, covalent inhibitor of Ubch5 with Kd values of 5.189 μM (Ubch5a), 3.578 μM (Ubch5b), and 2.577 μM (Ubch5c). The compound induces apoptosis in cancer cells. It modulates many processes that influence inflammatory reactions and has protective effects against atopic dermatitis-like skin inflammation. |
| ln Vivo |
In vivo, 1beta-hydroxyalantolactone reduces skin lesions resembling atopic dermatitis in mice exposed to 2,4-dinitrochlorobenzene. It has protective effects on cerebral ischemia-reperfusion injury. The compound inhibits the expression of TNF-α, IL-17, and IFN-γ in cells and has potential as a therapeutic agent for atopic dermatitis and rheumatoid arthritis. Further in vivo studies are needed to fully characterize its efficacy and safety.
|
| Enzyme Assay |
Non-cell-based assays for 1beta-hydroxyalantolactone include Ubch5 inhibition assays using purified recombinant Ubch5 enzymes. The enzyme is incubated with ubiquitin and E1 in the presence of various concentrations of the compound, and ubiquitin conjugation is measured using fluorescence or radiometric detection. Kd values are determined using surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC). NF-κB and MAPK inhibition can be assessed using kinase activity assays or reporter gene systems.
|
| Cell Assay |
Cell-based assays for 1beta-hydroxyalantolactone use various cell lines to assess its anti-inflammatory and anticancer activities. For anti-inflammatory studies, macrophage cell lines are stimulated with LPS and treated with the compound, and inflammatory cytokine production (TNF-α, IL-17, IFN-γ) is measured by ELISA. For anticancer studies, cancer cell lines are treated with the compound, and cell viability, apoptosis, and signaling pathway inhibition are assessed.
|
| Animal Protocol |
In vivo studies of 1beta-hydroxyalantolactone are conducted in mouse models. For atopic dermatitis evaluation, mice are exposed to 2,4-dinitrochlorobenzene to induce skin lesions, and the compound is administered topically or systemically. Skin lesion severity, inflammatory cytokine levels, and histopathology are assessed. For cerebral ischemia-reperfusion injury, mouse models of stroke are used. For rheumatoid arthritis, mouse models of inflammatory arthritis are used.
|
| ADME/Pharmacokinetics |
1beta-Hydroxyalantolactone has a molecular formula of C₁₅H₂₀O₃ and a molecular weight of approximately 248.32 g/mol. It is a sesquiterpene lactone isolated from Inula britannica. The compound should be stored at 2-8°C, protected from light, and sealed to prevent degradation. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for 1beta-hydroxyalantolactone are limited. The compound exhibits anti-inflammatory and anticancer activities, indicating biological activity at certain concentrations. It has protective effects against atopic dermatitis-like skin inflammation. Standard laboratory safety practices should be followed when handling this compound.
|
| References | |
| Additional Infomation |
1β-hydroxyarantoractone is a sesquiterpene lactone. It has been reported to exist in Inula japonica, Inula heliotropium, and Pentaclopramide, and relevant data are available.
1beta-Hydroxyalantolactone is a sesquiterpene lactone isolated from Inula britannica. It is a potent, covalent inhibitor of ubiquitin-conjugating enzyme Ubch5 with Kd values of 5.189 μM (Ubch5a), 3.578 μM (Ubch5b), and 2.577 μM (Ubch5c). The compound inhibits NF-κB and MAPK signaling pathways, reducing expression of pro-inflammatory cytokines (TNF-α, IL-17, IFN-γ). It has protective effects against atopic dermatitis-like skin inflammation and cerebral ischemia-reperfusion injury and is being studied for rheumatoid arthritis. It is for research use only. |
| Molecular Formula |
C15H20O3
|
|---|---|
| Molecular Weight |
248.32
|
| Exact Mass |
248.141
|
| CAS # |
68776-47-6
|
| PubChem CID |
71573444
|
| Appearance |
White to off-white solid
|
| Density |
1.17±0.1 g/cm3
|
| Boiling Point |
429.2±45.0 °C at 760 mmHg
|
| Flash Point |
183.4±21.5 °C
|
| Vapour Pressure |
0.0±2.3 mmHg at 25°C
|
| Index of Refraction |
1.555
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
18
|
| Complexity |
451
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
C[C@H]1CC[C@H]([C@]2(C)C[C@@H]3[C@H](C=C12)C(=C)C(=O)O3)O
|
| InChi Key |
FRNIMDDQCZHAFA-SCFTVSGOSA-N
|
| InChi Code |
InChI=1S/C15H20O3/c1-8-4-5-13(16)15(3)7-12-10(6-11(8)15)9(2)14(17)18-12/h6,8,10,12-13,16H,2,4-5,7H2,1,3H3/t8-,10+,12+,13+,15+/m0/s1
|
| Chemical Name |
(3aR,5S,8R,8aR,9aR)-8-hydroxy-5,8a-dimethyl-3-methylidene-5,6,7,8,9,9a-hexahydro-3aH-benzo[f][1]benzofuran-2-one
|
| Synonyms |
1beta-Hydroxyalantolactone
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0271 mL | 20.1353 mL | 40.2706 mL | |
| 5 mM | 0.8054 mL | 4.0271 mL | 8.0541 mL | |
| 10 mM | 0.4027 mL | 2.0135 mL | 4.0271 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
